Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis

Ebina, Kosuke; Hashimoto, Jun; Kashii, Masafumi; Hirao, Makoto; Miyama, Akira; Nakaya, Hiroyuki; Tsuji, Shigeyoshi; Takahi, Koichiro; Tsuboi, Hideki; Okamura, Gensuke; Etani, Yuki; Takami, Kenji; Yoshikawa, Hideki

doi:https://doi.org/10.1080/14397595.2020.1769895

Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis

Ebina, Kosuke; Hashimoto, Jun; Kashii, Masafumi et al.

Modern Rheumatology, 2021, 31(2), 485-492

アクセス数:1,339件（2025-07-17 13:56 集計）

固定URL: https://hdl.handle.net/11094/93250

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
ModRheumatol_31_2_485	pdf	なし	2.02 MB	62	2023.12.07

Creative Commons : 表示 - 非営利

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
著者	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 著者名 Ebina, Kosuke
	NRID 1000040237938 1000040237938 著者名 Hashimoto, Jun
	NRID 1000000576910 1000000576910 著者名 Kashii, Masafumi
	NRID 1000010527708 1000010527708 著者名 Hirao, Makoto
	著者名 Miyama, Akira
	著者名 Nakaya, Hiroyuki
	著者名 Tsuji, Shigeyoshi
	著者名 Takahi, Koichiro
	著者名 Tsuboi, Hideki
	著者名 Okamura, Gensuke
	NRID 1000060898930 1000060898930 著者名 Etani, Yuki
	著者名 Takami, Kenji
	NRID 1000060191558 1000060191558 著者名 Yoshikawa, Hideki
キーワード等	Bisphosphonate
	denosumab
	discontinuation
	follow-on treatment
	postmenopausal osteoporosis
内容	Ebina K., Hashimoto J., Kashii M., et al. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Modern Rheumatology 31, 485 (2021); https://doi.org/10.1080/14397595.2020.1769895.
抄録	Objectives: To clarify the effects of follow-on therapy after denosumab (DMAb) discontinuation. Methods: In this retrospective, multicenter study, postmenopausal patients with osteoporosis who were previously treated by oral bisphosphonates (BP) (n = 26) or teriparatide (TPTD) (n = 27) were switched to DMAb (administered 2.6 times), and then discontinued. Patients (73.1 years, T-scores of the lumbar spine [LS] − 2.7 and femoral neck [FN] − 2.2) were switched to either (1) raloxifene (RAL) (n = 13) or BP [(2) weekly or monthly BP (wmBP) (n = 29) or (3) zoledronate (ZOL) (n = 11)], based on each physician’s decision (mean interval after final DMAb administration was 7.2 months). Bone mineral density (BMD) at final DMAb administration were set as baseline. Results: Changes in LS BMD at 1.5 years after final DMAb administration were −2.7% in the RAL, 0.7% in the wmBP, and 1.9% in the ZOL (p =.31 between groups), and in FN BMD were −3.8%, −0.8%, and 1.8%, respectively (p =.02 between the RAL and ZOL; p =.048 between the RAL and BP). Clinical vertebral fracture incidence during 1.5 years after final DMAb administration was 23.1% in the RAL, 3.4% in the wmBP, and 0.0% in the ZOL (p =.048 between the RAL and ZOL; p =.015 between the RAL and BP). No significant differences were observed in these parameters between the wmBP and ZOL. Conclusion: These results may contribute to the selection of adequate follow-on therapy after DMAb discontinuation, although further investigations are required.
出版者	Taylor and Francis Ltd.
収録物名	Modern Rheumatology
巻(号)	31(2)
ページ	485-492
刊行年月	2021-03-04
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93250
PISSN	14397595
eISSN	14397609
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1080/14397595.2020.1769895
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
出版タイプ	Accepted Manuscript
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Modern Rheumatology. 2021, 31(2), p. 485-492
DC.title	Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
DC.creator	Ebina, Kosuke
	Hashimoto, Jun
	Kashii, Masafumi
	Hirao, Makoto
	Miyama, Akira
	Nakaya, Hiroyuki
	Tsuji, Shigeyoshi
	Takahi, Koichiro
	Tsuboi, Hideki
	Okamura, Gensuke
	Etani, Yuki
	Takami, Kenji
	Yoshikawa, Hideki
DC.publisher	Taylor and Francis Ltd.
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2021-03-04
DC.identifier	https://doi.org/10.1080/14397595.2020.1769895
DC.subject	Bisphosphonate
	denosumab
	discontinuation
	follow-on treatment
	postmenopausal osteoporosis
DC.description	Ebina K., Hashimoto J., Kashii M., et al. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Modern Rheumatology 31, 485 (2021); https://doi.org/10.1080/14397595.2020.1769895.
DCTERMS.abstract	Objectives: To clarify the effects of follow-on therapy after denosumab (DMAb) discontinuation. Methods: In this retrospective, multicenter study, postmenopausal patients with osteoporosis who were previously treated by oral bisphosphonates (BP) (n = 26) or teriparatide (TPTD) (n = 27) were switched to DMAb (administered 2.6 times), and then discontinued. Patients (73.1 years, T-scores of the lumbar spine [LS] − 2.7 and femoral neck [FN] − 2.2) were switched to either (1) raloxifene (RAL) (n = 13) or BP [(2) weekly or monthly BP (wmBP) (n = 29) or (3) zoledronate (ZOL) (n = 11)], based on each physician’s decision (mean interval after final DMAb administration was 7.2 months). Bone mineral density (BMD) at final DMAb administration were set as baseline. Results: Changes in LS BMD at 1.5 years after final DMAb administration were −2.7% in the RAL, 0.7% in the wmBP, and 1.9% in the ZOL (p =.31 between groups), and in FN BMD were −3.8%, −0.8%, and 1.8%, respectively (p =.02 between the RAL and ZOL; p =.048 between the RAL and BP). Clinical vertebral fracture incidence during 1.5 years after final DMAb administration was 23.1% in the RAL, 3.4% in the wmBP, and 0.0% in the ZOL (p =.048 between the RAL and ZOL; p =.015 between the RAL and BP). No significant differences were observed in these parameters between the wmBP and ZOL. Conclusion: These results may contribute to the selection of adequate follow-on therapy after DMAb discontinuation, although further investigations are required.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	93250
citation_title	Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
citation_author	Ebina, Kosuke
	Hashimoto, Jun
	Kashii, Masafumi
	Hirao, Makoto
	Miyama, Akira
	Nakaya, Hiroyuki
	Tsuji, Shigeyoshi
	Takahi, Koichiro
	Tsuboi, Hideki
	Okamura, Gensuke
	Etani, Yuki
	Takami, Kenji
	Yoshikawa, Hideki
citation_publisher	Taylor and Francis Ltd.
citation_language	英語
citation_date	2021-03-04
citation_journal_title	Modern Rheumatology
citation_volume	31
citation_issue	2
citation_firstpage	485
citation_lastpage	492
citation_doi	https://doi.org/10.1080/14397595.2020.1769895
citation_public_url	https://hdl.handle.net/11094/93250

Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis

閲覧可能ファイル

論文情報

論文詳細を表示